Modification of Intestinal Flora in the Treatment of Inflammatory Bowel Disease.

[Guest guest]

Medical Abstract Title:

Modification of Intestinal Flora in the Treatment of Inflammatory

Bowel Disease.

 

Author:

Kanauchi O, Mitsuyama K, Araki Y, Andoh A.

 

Source:

Curr Pharm Des. 2003;9(4):333-46.

 

Abstract:

 

Because the intestinal microflora play an important role in the

development of inflammatory bowel disease (IBD), there is currently

some interest in the manipulation of the composition of the

microflora towards a potentially more remedial community.

 

This review summarizes the clinical and experimental efficacy of the

manipulation of microflora by the use of prebiotics, probiotics,

synbiotics, and antibiotics in IBD.

 

Prebiotics, defined as nondigestible food ingredients that

beneficially affect the host by selectively stimulating the growth

or activity of one or a limited number of bacterial species already

resident in the colon, can modulate the colonic microbiota by

increasing the number of specific bacteria and thus changing the

composition of the microbiota.

 

Prebiotics for IBD include lactosucrose, oligofructose, inulin,

bran, psyllium, and germinated barley foodstuff (GBF).

 

GBF, which mainly consists of dietary fiber and glutamine-rich

protein, is a prebiotic foodstuff for ulcerative colitis.

 

GBF has shown to be converted into a preferential nutrient for

colonocytes through Eubacterium and Bifidobacterium and also

inactivate nuclear factor kappa B (NFkB). Moreover, it exhibits a

potent water-holding capacity and bile-acid binding capacity.

Probiotics, which are microbial food supplements that beneficially

affect the host by improving the intestinal microbial balance, have

been used to change the composition of colonic microbiota.

 

The approaches for IBD include VSL#3, Nissle1917, Clostridium

butyricum and Bifidobacterium-fermented milk. Use of Lactococci

secreting IL-10 provides excellent results. The combination of

prebiotics and probiotics in a synbiotic has not been studied in IBD

but is promising. Although these strategies hold great promise and

appear to be useful in some settings, more clinical study is needed

to firmly establish the relevance of these therapies.

www.enzy.com